A Phase 1b Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Anti-Tumor Activity of an Alternative Liquid Formulation of ACY-1215 (Ricolinostat) In Combination With Pomalidomide and Low-Dose Dexamethasone In Patients With Relapsed and Refractory Multiple Myeloma
Latest Information Update: 22 Nov 2019
At a glance
- Drugs Ricolinostat (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Acetylon Pharmaceuticals; Celgene Corporation
- 20 Nov 2019 Status changed from active, no longer recruiting to completed.
- 30 Apr 2018 Planned End Date changed from 15 Oct 2018 to 30 Jan 2019.
- 28 Nov 2017 Planned End Date changed from 3 Oct 2017 to 15 Oct 2018.